

IN THE SPECIFICATION:

Please insert the attached substitute sequence listing after the specification but before the claims.

On pages 18 and 19 of the specification, please replace Tables 1 and 2 with the following new tables:

Table 2. Estimation of VEGF family receptors MHC associated peptides in the context of HLA-A*02:01

A.- Using BIMAS software														
VEGFR-1			VEGFR-2			VEGFR-3			NRP-1			NRP-2		
SEQ ID	Secuencia	Kd	SEQ ID	Secuencia	Kd	SEQ ID	Secuencia	Kd	SEQ ID	Secuencia	Kd	SEQ ID	Secuencia	Kd
127	FLYRDVTWI	1942	137	VLLWEIFSL	1792	147	VLLWEIFSL	1793	157	GLLRFTAV	2249	167	WNIYDHAKVL	5121
128	VLLWEIFSL	1792	138	SLQDQGYV	769	148	RLLERKGV	1055	158	VLLGAVGV	1006	168	ILQFLIFDL	484
129	KLLRGHTLV	901	139	VLLAVALLV	739	149	VLPWQGEV	981	159	WMPENIRLV	436	169	YLQVDRFL	247
130	GLLTCEATV	257	140	AMFFWLLV	427	150	NLTDLNVV	656	160	GILSMVFT	278	170	ALYFSRHQV	223
131	TLFWLLTL	182	141	VIAIFFWLL	270	151	KQMERKVV	557	161	LLCAVALV	272	171	NNLOMISGL	131
132	ILLSNNVV	179	142	ILLSKNNV	179	152	GVIATFWV	369	162	VLLHKSIL	134	172	WLYTLPIL	129
133	TLNLTMNV	160	143	LLAVALWLC	146	153	KLVCNVAV	243	163	GHLGNVSG	131	173	DIWDGIPHV	56
134	CVAATLFWL	137	144	KNLDTLWKL	128	154	ALWNSAAGL	177	164	FQLTGGTV	120	174	KMEILQFL	44
135	LLSIKQNV	118	145	AVIAIFFWLL	113	155	TLSLSIPRV	160	165	VLAETKPTV	118	175	VNNKLHAPL	36
136	SLQDSGTVA	112	146	LLLVLIRT	108	156	SOHDLGSVY	159	166	GPRLFKEV	81	176	LLGATCAGL	36
B.- Using SYFPEITHI software														
VEGFR-1			VEGFR-2			VEGFR-3			NRP-1			NRP-2		
SEQ ID	Secuencia	Score	SEQ ID	Secuencia	Score	SEQ ID	Secuencia	Score	SEQ ID	Secuencia	Score	SEQ ID	Secuencia	Score
177	TLFWLLTL	29	187	VLLWEIFSL	29	197	VLLWEIFSL	29	207	VLLGAVGV	30	217	NNLOMISGL	27
178	VLLWEIFSL	29	188	LLVILRTV	28	198	SIFGLNVL	27	208	GLLRFTAV	29	218	ILQFLIFDL	26
179	ILPGSSTL	28	189	GLFKCTLTI	26	199	NLTDLNVV	27	209	LLCAVALV	28	219	DIWDGIPHV	26
180	LLCALLSCL	27	190	SIMYVVVV	26	200	VLPWQGEV	26	210	GHLGNVSG	28	220	YLQVDRFL	26
181	GLLTCEATV	27	191	ILVGTAVI	26	201	LLPRKSLEL	26	211	ALGVLGAV	28	221	TLDPILTI	26
182	LLRGHTLV	27	192	ALMSELKIL	26	202	ALWNSAAGL	26	212	VLLHKSIL	27	222	ILAKPKMEI	25
183	ALMTLKL	26	193	AAVGLPSV	25	203	IMPDSVPL	26	213	VLAETKPTV	26	223	VNNKLHAPL	25
184	KLLRGHTLV	25	194	SISNLNSL	25	204	RLWLCLGL	25	214	QLTGGTVL	25	224	LLGATCAGL	25
185	TLNLTMNV	25	195	AMFFWLLV	25	205	LIVFYTTI	25	215	VLLGAVGV	30	225	ALYFSRHQV	23
186	ILLSNNVV	25	196	ILLSKNNV	25	206	LLGEGPVL	25	216	GLLRFTAV	29	226	GIGIRLEV	23

Note: Values in bold correspond to those peptides or their regions, which coincide in both predictions.

On page 21 of the specification, please replace the paragraph beginning on line 9 with the following:

In the case of the extracellular domains 1 to 3 SEQ ID NO: ~~27~~ 23 and SEQ ID NO: ~~28~~ 24 (for domains 1-3) and SEQ ID NO: ~~29~~ and SEQ ID NO: ~~30~~ (for domain 3 alone), the primers used correspond to sequences SEQ ID NO: 9 and SEQ ID NO: 10. After digestion of the amplified fragment (943bp) ~~SEQ ID NO: 25 and SEQ ID NO: 26~~ with endonucleases BamHI and EcoRI, the cDNA coding 1-3 domains of KDR was purified, and cloned in pAECΔ2 vector. Clones positive by restriction analysis were verified by sequencing of the corresponding DNA. The cDNA corresponding to KDR 1-3 was then subcloned KpnI/EcoRV in the already described pMAE5Δ5 vector (pMAE5Δ5 KDR1-3).

For the cloning of transmembrane and cytosolic regions of the receptor (SEQ ID NO: 25 and SEQ ID NO: 26) a two-step strategy was designed. For the insertion of the first segment, the primers corresponding to SEQ ID NO: 11 and SEQ ID NO: 12 were used. After the XbaI/BglII digestion of this 747bp segment, the product was cloned in the pMAE5 vector, previously digested with the same enzymes, obtaining the plasmid pMAE5 KDR 747. This plasmid was digested BglII/NotI in order to insert the remaining carboxi-terminal fragment of 1091bp that was amplified using the primers corresponding to sequences SEQ ID NO: 13 and SEQ ID NO: 14. Clones positive by restriction analysis were verified by DNA sequencing and denominated pMAE5 KDR C.